| Entries |
| Document | Title | Date |
|---|
| 20090082384 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 03-26-2009 |
| 20090111846 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS - Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 04-30-2009 |
| 20090163530 | FAST DISSOLVING ORALLY CONSUMABLE FILMS - Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed. | 06-25-2009 |
| 20090176818 | Antitussive Agent - An antitussive, which can be used for therapy or prophylaxis of coughing, is disclosed. The antitussive comprises as an effective ingredient a morphinan derivative having a nitrogen-containing cyclic substituent or a pharmaceutically acceptable acid addition salt thereof, having a specific structure, such as the compound below [N-(17-cyclopeopylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-3,4,5,6-tetrahydrophthalimide]. The antitussive has an excellent therapeutic or prophylactic effect against coughing and the side effects thereof are small. | 07-09-2009 |
| 20090215810 | Method to Treat Premature Ejaculation in Humans - The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans. | 08-27-2009 |
| 20090253731 | Method of identifying therapeutic agents - The present invention relates to a method of identifying agents suitable for use in treating epilepsy and other brain disorders, including but not limited to bipolar disorder, schizophrenia and depression. The invention further relates to methods of treatment based on the use of agents so identifiable. | 10-08-2009 |
| 20090312361 | NOVEL PHARMACEUTICAL COMPOSITIONS FOR TREATING ACQUIRED CHRONIC PAIN AND ASSOCIATED DYSPHORIA - Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular entity, and a methylxanthine such as caffeine, and optionally in sustained release dosage form. | 12-17-2009 |
| 20100004278 | DEXTROMETHORPHAN HYDROCHLORIDE - The present invention provides pharmaceutical compositions comprising dextromethorphan hydrochloride. | 01-07-2010 |
| 20100029704 | SALT OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG AND ORGANIC AMINE COMPOUND AND USE THEREOF - The invention provides a salt, particularly an ionic liquid, of a non-steroidal anti-inflammatory drug (NSAID) comprising a carboxylic acid and an organic amine compound, as well as a method of producing such a salt. | 02-04-2010 |
| 20100113500 | ORALLY BIOAVAILABLE PRODUCTS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT - The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease. | 05-06-2010 |
| 20100137352 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 06-03-2010 |
| 20100144777 | Method of Network-Based Identification of Multicomponent Synergy and Compositions for Use as Effective Component of Anti-Angiogenesis Medicines - A method was provided for determining synergistic effect of a medicine combination including two medicines relating to a disease on the basis of a gene network and medicine-effective genes of each and/or any of said two medicines, comprising: determining a synergy factor (ST | 06-10-2010 |
| 20100216830 | Oral Composition Comprising A Cooling Agent - The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between −10 cal/g and −100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at an amount less than 10% w/w. | 08-26-2010 |
| 20100240691 | MORPHINAN DERIVATIVES WITH HIGH ORAL BIOAVAILABILITY - The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction. | 09-23-2010 |
| 20100311786 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS - Disclosed are compounds that block off-notes in consumables and methods of blocking off-notes in consumables including off-notes provided by sweeteners such as stevioside, swingle extract, glyccerhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A, and artificial sweeteners such as aspartame, saccharin, acesulfame K (Acesulfame potassium), sucralose and cyclamate. | 12-09-2010 |
| 20110021552 | Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Depression, Anxiety, and Neurodegenerative Disorders - Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 01-27-2011 |
| 20110039875 | PHARAMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY - The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and/or a tricyclic antidepressant. | 02-17-2011 |
| 20110065744 | Method Of Inhibiting Mucin Secretion - A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin. | 03-17-2011 |
| 20110071183 | MANUFACTURE OF LOZENGE PRODUCT WITH RADIOFREQUENCY - The present invention features a process for making a lozenge product including the steps of forming a powder blend containing an amorphous carbohydrate polymer into the desired shape of the lozenge product and applying radiofrequency energy to the shape for a sufficient period of time to soften or melt said amorphous carbohydrate polymer to fuse the shape into said lozenge product. | 03-24-2011 |
| 20110136851 | Sucralose Formulations To Mask Unpleasant Tastes - The present invention is directed to a pharmaceutically acceptable taste masking liquid excipient base for administration of a relatively large amount of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addition of sucralose to the excipient base with maintenance of a pH from about 2 to about 5. The invention is further directed to medicinal compositions comprising such a liquid excipient base and unpleasant tasting medicines. Still further, the invention is directed to a method for taste masking unpleasant tasting medicines through their incorporation into the claimed liquid excipient bases. | 06-09-2011 |
| 20110212987 | METHOD OF REDUCING CNS AND GASTROINTESTINAL SIDE AFFECTS ASSOCIATED WITH LONG-TERM DEXTROMETHORPHAN/LOW-DOSE QUINIDINE COMBINATION THERAPY - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. This invention also provides methods of reducing CNS and gastrointestinal side effects associated with a long term, dextromethorphan/low-dose quinidine combination therapy. | 09-01-2011 |
| 20110218213 | Methods and Compositions for Treating or Preventing Symptoms of Hormonal Variations - The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations. The receptor antagonist binds to at least one receptor selected from a serotonin type 2A (5-HT.sub.2A) and/or a dopamine type 2 (D.sub.2) receptors. | 09-08-2011 |
| 20110230514 | Morphinan Compounds - This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 09-22-2011 |
| 20110237616 | PHEHYLEPHRINE FORMULATIONS WITH IMPROVEDS STABILITY - A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity. | 09-29-2011 |
| 20110251230 | THERAPEUTICS FOR NEUROLOGICAL DISORDERS - The present invention relates to therapeutic compounds that are Nrf2-ARE pathway activators suitable for the treatment of diseases known to be mediated by oxidative stress such as motor neurone disease. The invention also includes compounds identified by methods of the invention for treatment of neurogenerative diseases. | 10-13-2011 |
| 20110257214 | MORPHINAN COMPOUNDS - This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity. | 10-20-2011 |
| 20110281904 | Use of Dextromethorphan in Treating Addictive Behavior or Bipolar Disorder - The present invention provides a method for treating addictive behavior, comprising administering Dextromethorphan (DM) to a subject suffering addictive behavior. The present invention also provides a method for treating bipolar disorder, comprising administering Dextromethorphan (DM) to a subject suffering bipolar disorder. | 11-17-2011 |
| 20110281905 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 11-17-2011 |
| 20120065221 | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use - The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof. | 03-15-2012 |
| 20120165363 | Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 06-28-2012 |
| 20120172388 | Enhancement of Impaired Motor and Mental Functions, Using Dextromethorphan and Oxidase Enzyme Inhibitor - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 07-05-2012 |
| 20120190704 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF - The invention relates to compounds that are substituted azaadamantane ester and carbamate derivatives, compositions comprising such compounds, and methods of using such compounds and compositions. | 07-26-2012 |
| 20120258981 | Process for the Synthesis of Quaternary Amine Compounds - The invention relates to a process for the synthesis of quaternized compounds of formula: | 10-11-2012 |
| 20120264776 | MENTHOL LIQUIDS COMPOSITION - A liquid antitussive composition comprising about 0.05 grams to about 0.2 grams of menthol per 100 ml of liquid antitussive composition, a solvent system, and a surfactant, wherein the composition has a maximum alcohol content of about 0.5 grams per 100 ml of the liquid antitussive composition, and wherein the composition is stable for about 6 months at 40° C., 75% relative humidity conditions. | 10-18-2012 |
| 20130053411 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION - Dextromethorphan is used to lower blood pressure in a subject suffering from hypertension, alone or in combination with another anti-hypertensive agent. In particular, dextromethorphan acts synergistically with a calcium channel blocker, such as amlodipine, to result in a major improvement in the treatment of hypertension, with no or little adverse effects. | 02-28-2013 |
| 20130072517 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 03-21-2013 |
| 20130123295 | TREATMENT OF NEUROPATHIC PAIN WITH N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONISTS - Central neuropathic pain is treated with an analgesic composition that consists essentially of an N-methyl-D-aspartate (NMDA) receptor antagonist. In one embodiment, the invention includes chronic administration of the (NMDA) receptor antagonist. In another embodiment, the invention is use of an NMDA receptor antagonist or component thereof for the manufacture of a medicament than includes an analgesic component that consists essentially of an NMDA receptor antagonist for the chronic treatment of central neuropathic pain. | 05-16-2013 |
| 20130137714 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS - Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 05-30-2013 |
| 20130150396 | Solubilization and Bioavailability of Acetaminophen - A composition for increasing the bioavailability of Acetaminophen in humans and animals, comprising Acetaminophen, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C. | 06-13-2013 |
| 20130165470 | Methods for Detecting and Treating Rhinovirus Infection - The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided. | 06-27-2013 |
| 20130190346 | METHOD OF REDUCING CNS AND GASTROINTESTINAL SIDE AFFECTS ASSOCIATED WITH LONG-TERM, DEXTROMETHORPHAN/LOW-DOSE QUINIDINE COMBINATION THERAPY - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. This invention also provides methods of reducing CNS and gastrointestinal side effects associated with a long term, dextromethorphan/low-dose quinidine combination therapy. | 07-25-2013 |
| 20130225627 | DEXTROMETHORPHAN ANTITUSSIVE COMPOSITIONS - The invention provides orally administered antitussive pharmaceutical compositions comprising dextromethorphan, wherein the compositions are free of bromide, sodium and polistirex. | 08-29-2013 |
| 20130225628 | CARBOXAMIDE BIOISOSTERES OF OPIATES - A compound of formula I is disclosed. | 08-29-2013 |
| 20130231361 | 4-HYDROXYBENZOMORPHANS - 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. A compound of formula | 09-05-2013 |
| 20130237559 | SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID - The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an amine-containing compound (e.g., an opioid) (including salts thereof) and a pharmaceutically acceptable salt of a non-NSAID cyclic organic acid compound. | 09-12-2013 |
| 20130245057 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS - The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, to a subject having one or more symptoms of hormonal variations. | 09-19-2013 |
| 20130274282 | COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN - Pain and/or neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as celecoxib that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein. | 10-17-2013 |
| 20130310415 | MORPHINAN COMPOUNDS - This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 11-21-2013 |
| 20130317052 | QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal mobility disorders. | 11-28-2013 |
| 20130338182 | NOVEL MORPHINANS USEFUL AS ANALGESICS - Compounds of Formula (I) are disclosed. | 12-19-2013 |
| 20140045880 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 02-13-2014 |
| 20140051718 | Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan - Neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as celecoxib that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein. | 02-20-2014 |
| 20140148475 | 4-HYDROXYBENZOMORPHANS - 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. A compound of formula | 05-29-2014 |
| 20140187573 | Substituted Morphinans and the Use Thereof - The application is directed to compounds of Formula I: | 07-03-2014 |
| 20140200237 | Compositions of (-)-17-(Cyclobutylmethyl) Morphinan-3,14-Diol - The present invention is directed to oral, therapeutically effective modified release pharmaceutical compositions of (−)-17-(cyclobutylmethyl)morphinan-3,14-diol and it pharmaceutically acceptable salts and the use thereof, including delayed onset and extended release dosage forms. The present invention is also directed at modified release dosage forms of oral (−)-17-(cyclobutylmethyl)morphinan-3,14-diol which provide robust efficacy and reduced potential for abuse and misuse. | 07-17-2014 |
| 20140213607 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USINGDEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 07-31-2014 |
| 20140213608 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 07-31-2014 |
| 20140243364 | ENHANCED STABILITY OF NOVEL LIQUID COMPOSITIONS - The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions. | 08-28-2014 |
| 20140249173 | GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS - Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided. | 09-04-2014 |
| 20140275151 | DYE FREE LIQUID THERAPEUTIC SOLUTION - A liquid composition is provided. The composition includes at least one active pharmaceutical ingredient dissolved in a liquid carrier system. The liquid carrier includes polyethylene glycol and a co-solvent selected from the group consisting of: propylene glycol, glycerin, and a sugar alcohol. The composition is essentially dye tree, present as a single-phase at room temperature, and optionally contains water. | 09-18-2014 |
| 20140288114 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 09-25-2014 |
| 20140315940 | MORPHINAN COMPOUNDS - This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 10-23-2014 |
| 20140315941 | METHOD OF REDUCING CNS AND GASTROINTESTINAL SIDE AFFECTS ASSOCIATED WITH LONG-TERM, DEXTROMETHORPHAN/LOW-DOSE QUINIDINE COMBINATION THERAPY - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. This invention also provides methods of reducing CNS and gastrointestinal side effects associated with a long term, dextromethorphan/low-dose quinidine combination therapy. | 10-23-2014 |
| 20140378499 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS - The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, to a subject having one or more symptoms of hormonal variations. | 12-25-2014 |
| 20150025103 | ORAL LIQUID CONCENTRATE COMPRISING BROMPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN - There is provided a liquid oral concentrate comprising combination of dextromethorphan, bromrpheniramine and pseudoephedrine or pharmaceutically acceptable salts thereof. The invention further provides process for preparation of such compositions. | 01-22-2015 |
| 20150045384 | Morphan and Morphinan Analogues, and Methods of Use - The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof. | 02-12-2015 |
| 20150073009 | MORPHINAN COMPOUNDS - This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 03-12-2015 |
| 20150087669 | Morphinan-derivatives for treating diabetes and related disorders - The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I) | 03-26-2015 |
| 20150087670 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants, upper respiratory infections, (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis, neuropathic pain and pain associated with fibromyalgia. | 03-26-2015 |
| 20150099776 | Beta-Amyloid-Directed Multitarget Compounds For The Treatment Of Alzheimer's Disease - The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R | 04-09-2015 |
| 20150126541 | COMPOSITIONS AND METHODS FOR REDUCING DEXTRORPHAN PLASMA LEVELS AND RELATED PHARMACODYNAMIC EFFECTS - This disclosure relates to methods of decreasing dextrorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed. | 05-07-2015 |
| 20150126542 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects - This disclosure relates to methods of increasing the metabolic lifetime of dextromethorphan administering threohydroxybupropion or a prodrug thereof to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or a prodrug of theohydroxybupropion are also disclosed. | 05-07-2015 |
| 20150126543 | COMPOSITIONS AND METHODS COMPRISING ERYTHROHYDROXYBUPROPION AND RELATED COMPOUNDS FOR IMPROVING THE EFFICACY OF DEXTROMETHORPHAN - This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed. | 05-07-2015 |
| 20150126544 | COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 05-07-2015 |
| 20150133485 | COMPOSITIONS AND METHODS OF USING THREOHYDROXYBUPROPION FOR THERAPEUTIC PURPOSES - This disclosure relates to methods administering threohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or a prodrug of threohydroxybupropion are also disclosed | 05-14-2015 |
| 20150133486 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed | 05-14-2015 |
| 20150306050 | Medications For Deposition On Biological Surfaces - Personal care compositions, such as oral medication compositions containing a flavor system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater intensity, impact or longer duration, which improves appeal and acceptability of the compositions to consumers. | 10-29-2015 |
| 20150376197 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE - The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof. | 12-31-2015 |
| 20160008352 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 01-14-2016 |
| 20160008353 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS | 01-14-2016 |
| 20160015684 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS - Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable for oral administration in the amount present, wherein the composition is orally bioavailable when administered to a subject. The bioreversible derivative has an intrinsic lipophilicity C log P value of about 7 to about 11.5. A method comprises oral administering such composition to a human subject in need of hydroxy N-substituted-2-aminotetralin therapy. | 01-21-2016 |
| 20160015815 | PHENYLEPHRINE FORMULATIONS WITH IMPROVED STABILITY - A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity. | 01-21-2016 |
| 20160030418 | METHOD FOR DECREASING LOW DENSITY LIPID PROTEIN - The present invention relates to a method of decreasing cholesterol or low density lipid protein in a subject in need thereof comprising: administering to said subject a pharmaceuticaly effective amount of a composition comprising dextromethorphan. | 02-04-2016 |
| 20160030420 | COMPOSITIONS AND METHODS FOR INCREASING DEXTROMETHORPHAN PLASMA LEVELS AND RELATED PHARMACODYNAMIC EFFECTS - This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed. | 02-04-2016 |
| 20160030421 | COMPOSITIONS AND METHODS COMPRISING ERYTHROHYDROXYBUPROPION AND RELATED COMPOUNDS FOR IMPROVING THE EFFICACY OF DEXTROMETHORPHAN - This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed. | 02-04-2016 |
| 20160045491 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 02-18-2016 |
| 20160045492 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 02-18-2016 |
| 20160051475 | Sustained Release Composition Comprising an Amine as Active Agent and a Salt of a Cyclic Organic Acid - The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an amine-containing compound (e.g., an opioid) (including salts thereof) and a pharmaceutically acceptable salt of a non-NSAID cyclic organic acid compound. | 02-25-2016 |
| 20160051538 | METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN - The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient. | 02-25-2016 |
| 20160128998 | Compositions and Methods Comprising Bupropion or Related Compounds for Sustained Delivery of Dextromethorphan - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 05-12-2016 |
| 20160136155 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects - This disclosure relates to methods of increasing the metabolic lifetime of dextromethorphan administering threohydroxybupropion or bupropion to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or bupropion are also disclosed. | 05-19-2016 |
| 20160143901 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA - This disclosure provides pharmaceutical compositions comprising dextromethorphan in combination with quinidine, and methods for treating agitation and/or aggression in subjects with dementia by administering such compositions. | 05-26-2016 |
| 20160143902 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY - Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like. | 05-26-2016 |
| 20160184290 | METHOD OF TREATING SCHIZOPHRENIA - A method of treating symptoms of schizophrenia includes enterically administering to a subject a pharmacological agent that inhibits presynaptic glutamate release, modulates postsynaptic glutamate response, or both. | 06-30-2016 |
| 20160199321 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 07-14-2016 |
| 20160375008 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 12-29-2016 |
| 20160375012 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects - This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed | 12-29-2016 |
| 20190142768 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 05-16-2019 |
